Eltrombopag, a thrombopoietin receptor agonist, is used to treat thrombocytopenia, particularly immune thrombocytopenic purpura (ITP). It has shown a dose-dependent response to increase platelet counts in patients with chronic ITP.
Stem cells are crucial in treating thrombocytopenia, especially in stem cell transplantation. Eltrombopag, an orally available thrombopoietin receptor agonist, has shown promising results in treating persistent thrombocytopenia post-SCT.